To include your compound in the COVID-19 Resource Center, submit it here.

Thymoglobulin: Phase IIa results; marketed to prevent rejection of renal transplants

SANG said that in a Canadian Phase IIa study of 69 patients with

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE